Search alternatives:
significant advancements » significant advancement (Expand Search), significant advantages (Expand Search), significant improvements (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
Showing 18,161 - 18,180 results of 21,342 for search '(( significant advancements decrease ) OR ( significant decrease decrease ))', query time: 0.53s Refine Results
  1. 18161
    Image 3_HIF‐1α modulates pancreatic cancer ECM proteins via the TGF‐β1/Smad signaling pathway introduction.tif

    Image 3_HIF‐1α modulates pancreatic cancer ECM proteins via the TGF‐β1/Smad signaling pathway introduction.tif by Houle Guo (21264647)

    Published 2025
    “…Pharmacological inhibition of either HIF-1α or TGF-β1 significantly decreased the expression of ECM proteins, while TGF-β1 stimulation enhanced their production. …”
    Save to List
    Saved in:
  2. 18162
    Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.pdf

    Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
    Save to List
    Saved in:
  3. 18163
    Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.xlsx

    Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
    Save to List
    Saved in:
  4. 18164
    Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.xlsx

    Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
    Save to List
    Saved in:
  5. 18165
    Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.xlsx

    Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
    Save to List
    Saved in:
  6. 18166
    Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.xlsx

    Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
    Save to List
    Saved in:
  7. 18167
    Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.xlsx

    Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

    Published 2024
    “…Known associations between genomic alterations and immunotherapy markers were observed including significantly lower TMB levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, MET, BRAF, or ROS1 driver mutations. …”
    Save to List
    Saved in:
  8. 18168
    Data Sheet 5_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls

    Data Sheet 5_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

    Published 2025
    “…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”
    Save to List
    Saved in:
  9. 18169
    Data Sheet 3_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls

    Data Sheet 3_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

    Published 2025
    “…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”
    Save to List
    Saved in:
  10. 18170
    Data Sheet 6_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls

    Data Sheet 6_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

    Published 2025
    “…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”
    Save to List
    Saved in:
  11. 18171
    Data Sheet 1_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls

    Data Sheet 1_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

    Published 2025
    “…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”
    Save to List
    Saved in:
  12. 18172
    Data Sheet 2_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls

    Data Sheet 2_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

    Published 2025
    “…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”
    Save to List
    Saved in:
  13. 18173
    Data Sheet 4_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls

    Data Sheet 4_Overexpression of NK4 gene in TU212 affects migratory activity in laryngeal squamous cell carcinoma.xls by Yixuan Huo (21783825)

    Published 2025
    “…Functional experiments showed that PLV-NK4-TU212 cells exhibited a significantly reduced migration rate, decreased proliferative ability, and increased apoptosis rate. …”
    Save to List
    Saved in:
  14. 18174
    HK2 regulates mRNA translation in melanoma cells.

    HK2 regulates mRNA translation in melanoma cells. by Ana Luisa Dian (22258504)

    Published 2025
    “…HK2 depletion significantly decreased the abundance of <i>SOX10</i>, <i>CDH2</i>, and <i>WNT5A</i> mRNAs extracted from polysome fractions, but not in total RNAs. …”
    Save to List
    Saved in:
  15. 18175
    VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals.

    VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals. by G. Robert Aguilar (13889674)

    Published 2025
    “…(<b>B</b>) In <i>hlh-17/31/32</i><sup>null</sup> mutants, <i>flp-32(syb4374)</i> reporter allele expression in VB2 is decreased, reaching the same level of expression as that in VB1. …”
    Save to List
    Saved in:
  16. 18176
    C2f and BC2f module structure diagrams.

    C2f and BC2f module structure diagrams. by Yaojun Zhang (389482)

    Published 2025
    “…This study presents an advanced drone smoke detection model, YOLOv8n-BWG, building on YOLOv8. …”
    Save to List
    Saved in:
  17. 18177
    Image 10_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg

    Image 10_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

    Published 2025
    “…In vivo, RBM15 depletion significantly delayed tumor progression and enhanced CD8⁺ T cell infiltration and activation in the tumor microenvironment.…”
    Save to List
    Saved in:
  18. 18178
    Image 3_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg

    Image 3_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.jpeg by Chen Wang (88408)

    Published 2025
    “…In vivo, RBM15 depletion significantly delayed tumor progression and enhanced CD8⁺ T cell infiltration and activation in the tumor microenvironment.…”
    Save to List
    Saved in:
  19. 18179
    YOLOv8n detection results diagram.

    YOLOv8n detection results diagram. by Yaojun Zhang (389482)

    Published 2025
    “…This study presents an advanced drone smoke detection model, YOLOv8n-BWG, building on YOLOv8. …”
    Save to List
    Saved in:
  20. 18180
    Image 7_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif

    Image 7_RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.tif by Chen Wang (88408)

    Published 2025
    “…In vivo, RBM15 depletion significantly delayed tumor progression and enhanced CD8⁺ T cell infiltration and activation in the tumor microenvironment.…”
    Save to List
    Saved in:

Search Tools: